OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
August 02, 2016
CMOs are working hard to improve performance by investigating new technologies for filtration and purification.
CMOs that offer an innovative service-oriented model will dominate the industry.
August 01, 2016
Stability testing programs should provide drug owners the information needed to establish the proper handling, shipping, and shelf-life recommendations for drug products.
The success of a pharmaceutical manufacturing transfer from one facility to another requires detailed operational plans, attention to detail, and coordination between all parties. \
Quality, innovation, and new approval pathways open drug development options for the Chinese market, including injectable contract manufacturing.
Bio/pharmaceutical contract service provides continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.
New approaches add flexibility and reduce risk for contract development and manufacturing organizations (CDMOs) and their clients.
Planning ahead is key to enabling a continuous and secure supply chain that adapts to changes in market demand.
Now past the “wait-and-see” standoff, most pharmaceutical companies and their contract partners are considering long-term requirements, including distributors’ needs.
The author reviews some of the key considerations when selecting a vendor and crucial parameters that must be defined in the tech-transfer process to ensure the greatest chance of success.